United States Patent 4,405,598 Landscape: Scope, Claim Coverage, and Competitive Risk for Disodium Cromoglycate Metered-Dose Inhalation (CFC/HFC-Free Propellant System)
Executive summary: U.S. Patent 4,405,598 is a focused claim set covering (i) a method of treating asthma using an inhalation composition and (ii) the inhalation composition itself, where the composition is defined by a tight set of parameters: particle-size distribution of disodium cromoglycate, sorbitan/sorbitol ester surfactant level, specific binary propellant mixture of dichlorodifluoromethane (CFC-12 analog) and 1,2-dichloro-1,1,2,2-tetrafluoroethane (HCFC-124 analog) with no/“substantially no” trichloromonofluoromethane, a defined weight ratio (2:1 to 1:1), and very low water content with a vapor pressure window (35–70 psig). The enforceable commercial threat is strongest for products that match the same dispersion/suspension particle size and propellant composition constraints; it is weaker for alternatives that alter the propellant identity, propellant ratio, water content, or mass median diameter (MMD) range.
What is US Patent 4,405,598 protecting: asthma treatment method and inhalation composition claims?
Quick answer: The patent protects a specific formulation and its use in asthma treatment. Independent claim 1 covers a method and claim 3 covers the composition (with “consisting essentially of” propellant constraints). The claims are not broadly “disodium cromoglycate inhalation” claims; they are constrained to a specific propellant binary system and a specific aerosol/science profile (particle size, water content, surfactant level, and vapor pressure).
Claim set structure
- Claim 1 (method of treatment):
- Treatment of asthma
- Administration of inhalation composition with:
- Disodium cromoglycate:
- 0.2 to 2.0% by mass
- Mass median diameter 0.01 to 10 microns
- Water content of the disodium cromoglycate ingredient: 0.05 to 1% w/w
- Surfactant:
- 0.15 to 2.0% w/w of a sorbitan or sorbitol ester
- Propellant mixture:
- Dichlorodifluoromethane + 1,2-dichloro-1,1,2,2-tetrafluoroethane
- Substantially no trichloromonofluoromethane
- Weight ratio dichlorodifluoromethane : 1,2-dichloro-1,1,2,2-tetrafluoroethane = 2:1 to 1:1
- Total formulation water: < 0.1% w/w
- Vapor pressure 35 to 70 psig
- Claim 2 (dependent method):
- Adds a particle distribution constraint:
- at least 50% by weight of disodium cromoglycate particles are 2 to 5 microns
- Adds a narrower surfactant band:
- 0.2 to 1.2% by weight surfactant
- Claim 3 (composition):
- Mirrors claim 1 composition parameters, with:
- Propellant defined as “consisting essentially of” dichlorodifluoromethane and 1,2-dichloro-1,1,2,2-tetrafluoroethane
- Ratio constraint and water/vapor pressure constraints retained
- Surfactant and disodium cromoglycate constraints retained
- Disodium cromoglycate water: 0.05 to 1% w/w
- Total formulation water: < 0.1% w/w
- Vapor pressure 35–70 psig
Key implication: Claim 1 and 3 are composition-parameter dependent. Even if a product treats asthma with disodium cromoglycate, it avoids coverage if it falls outside any material limitation, especially the propellant system and aerosol particle size/water/vapor pressure boundaries.
How broad are the claims: does “mass median diameter 0.01 to 10 microns” create full coverage?
Quick answer: The MMD range is wide, but the claim still requires other tight formulation constraints. In practice, “avoidance” is likely achieved by changing the propellant system, surfactant selection/level, water content, and/or vapor pressure, not by moving MMD slightly within 0.01–10 microns.
MMD scope and boundary behaviors
- MMD 0.01 to 10 microns is broad on its face.
- The claim also requires:
- disodium cromoglycate at 0.2–2.0%
- disodium cromoglycate water at 0.05–1%
- total water <0.1%
- vapor pressure 35–70 psig
- surfactant 0.15–2.0% (or 0.2–1.2% in claim 2)
- propellant identity and ratio constraints.
Risk posture: A generic or follow-on product that matches MMD but uses:
- a different propellant blend,
- a different ratio outside 2:1 to 1:1,
- water content outside <0.1% total, or
- vapor pressure outside 35–70 psig,
is likely outside the claim.
Dependent claim 2 adds a second particle-size limiter
Claim 2 narrows further:
- at least 50% of particles between 2 and 5 microns
- surfactant 0.2–1.2%
Implication for design-around: A product can aim to fall within claim 1 composition parameters but fail claim 2 by using a distribution not meeting the “>=50% by weight 2–5 microns” constraint.
What propellant system limitations drive infringement risk: dichlorodifluoromethane + 1,2-dichloro-1,1,2,2-tetrafluoroethane?
Quick answer: The propellant definition is the largest “hard boundary” in the claims. A product using a different propellant (even with similar vapor pressure) will typically avoid the claims if it does not use the specified dichlorodifluoromethane/1,2-dichloro-1,1,2,2-tetrafluoroethane combination in the specified ratio and purity constraints.
Claim language differences: “substantially no” vs “consisting essentially of”
- Claim 1: “propellant mixture comprising … and containing substantially no trichloromonofluoromethane”
- Claim 3: “propellant mixture consisting essentially of …” the two specified components
Infringement design effect:
- “Substantially no” can be litigated around trace impurities. The “consisting essentially of” language in claim 3 creates a stricter exclusion of additional components beyond what is unavoidable.
Ratio window: 2:1 to 1:1
- Dichlorodifluoromethane : 1,2-dichloro-1,1,2,2-tetrafluoroethane must be between 2:1 and 1:1 by weight.
- This is a measurable parameter. A blend prepared to a narrower ratio outside the window is a straightforward potential design-around.
Vapor pressure constraint: 35–70 psig
- Vapor pressure is a formulation property influenced by propellant composition, temperature, and additional volatiles.
- Even if the propellants match, vapor pressure outside 35–70 psig breaks the claim.
What formulation “water content” requirements constrain design-arounds?
Quick answer: The claims require both ingredient-specific water and total formulation water constraints, which are less commonly targeted in competitive formulation redesign.
Disodium cromoglycate water content (ingredient-level)
- disodium cromoglycate used contains 0.05 to 1% w/w water
Total formulation water content
- total formulation contains <0.1% w/w water
Practical meaning for competitors:
- Even with correct propellant identity and ratios, a product with higher residual moisture can fall outside the claim.
- Moisture can be affected by:
- manufacturing humidity,
- drying steps,
- packaging moisture ingress,
- raw material grade/conditioning.
What patents likely surround US 4,405,598: how to think about claim-coverage adjacency?
Quick answer: Without a full prosecution file or the rest of the family, the most reliable inference is that the estate clusters around:
- CFC/HCFC propellant + disodium cromoglycate suspension formulations,
- aerosol particle engineering for cromoglycate delivery,
- surfactant selection (sorbitan/sorbitol esters),
- moisture control and vapor pressure targeting.
This patent’s constraints suggest it is part of a formulation-focused prosecution program, where close patents typically cover:
- different propellant blends (other freons),
- alternative surfactants (not sorbitan/sorbitol esters or different levels),
- alternative particle size distributions (not meeting MMD or “>=50% 2–5 microns”),
- alternative water targets/vapor pressure bands,
- alternative medical indications or method-of-use framing.
Actionable read-through: The enforceable “narrow corridor” is the combination of:
- binary propellant identity + ratio + no trichloromonofluoromethane
- moisture limits
- vapor pressure window
- sorbitan/sorbitol ester surfactant range
- cromoglycate particle size distribution
Competitors aiming for freedom-to-operate for asthma inhalation with disodium cromoglycate usually change one or more of these “axes.”
Does the patent cover any asthma method, or only administration of this exact inhalation composition?
Quick answer: Only the method of treating asthma through administration of this exact formulation profile. The method claim is not an abstract treatment method.
Method claim dependence on composition parameters
Claim 1 is essentially a “use” claim tied to every composition feature:
- effective amount of the inhalation composition
- with the specific dispersion/suspension and propellant system
- plus the water and vapor pressure constraints
Infringement requirement: If any required parameter is absent (for example propellant ratio outside window or water exceeds limits), the method claim likely fails as well.
What is the Orange Book status relevance for US 4,405,598?
Quick answer: The claims are formulation-centric for inhalation aerosol with specific propellant chemistry. Orange Book listing is relevant only if the drug is approved with those patents listed for the referenced application. The patent’s claim style is typical of older inhaler formulations and may or may not be listed in current Orange Book records for today’s marketed products.
What generic entry risks exist: when can a filer land without infringing?
Quick answer: The most credible generic/follow-on “safe lanes” are:
- propellant switch away from the specified dichlorodifluoromethane/1,2-dichloro-1,1,2,2-tetrafluoroethane system,
- ratio outside 2:1 to 1:1,
- vapor pressure outside 35–70 psig,
- moisture control outside ingredient-level and total formulation limits,
- surfactant change away from sorbitan/sorbitol ester at the required level,
- particle size distribution failing either claim 1 MMD range or claim 2 “>=50% 2–5 microns” distribution.
Practical “risk hot spots”
- Products that reproduce the same freon blend and particle sizing process are the highest risk.
- Litigation around moisture and vapor pressure can turn on measurement methods and lot variability.
Which downstream product characteristics map to claim limitations: dosage, particle sizing, and surfactant?
Quick answer: The claims do not specify device type (MDI vs nebulizer) in the text you provided, but the presence of a propellant mixture strongly suggests an aerosol metered-dose inhaler context. Coverage depends on meeting formulation parameters.
Formulation parameter matrix (how to read claim scope)
| Parameter |
Claim 1 requirement |
Claim 2 additional requirement |
Claim 3 requirement |
| Disodium cromoglycate % |
0.2–2.0% w/w |
same |
0.2–2.0% w/w |
| Disodium cromoglycate MMD |
0.01–10 microns |
same |
0.01–10 microns |
| Cromoglycate water |
0.05–1% w/w |
same |
0.05–1% w/w |
| Surfactant type |
sorbitan or sorbitol ester |
sorbitan/sorbitol ester |
sorbitan or sorbitol ester |
| Surfactant level |
0.15–2.0% w/w |
0.2–1.2% w/w |
0.15–2.0% w/w |
| Particle distribution |
not specified |
>=50% by weight 2–5 microns |
not specified |
| Propellants |
dichlorodifluoromethane + 1,2-dichloro-1,1,2,2-tetrafluoroethane |
same |
“consisting essentially of” those two |
| Other propellant |
substantially no trichloromonofluoromethane |
same |
none beyond ESSENTIAL scope |
| Propellant ratio |
2:1 to 1:1 (w/w) |
same |
2:1 to 1:1 (w/w) |
| Total water |
<0.1% w/w |
same |
<0.1% w/w |
| Vapor pressure |
35–70 psig |
same |
35–70 psig |
How does US 4,405,598 compare with typical asthma inhalation patent estates (cromoglycate vs other mast-cell stabilizers)?
Quick answer: Relative to broader asthma inhaler patents, this one is more chemistry-specific. Many asthma inhalation patents claim:
- different active ingredients,
- different delivery devices,
- different particle sizes without binding propellant chemistry.
Here, the “tight coupling” between:
- a particular freon blend,
- specific surfactant chemistry,
- controlled moisture,
- measured aerosol sizing,
makes the estate narrower.
Commercial consequence: If the market has shifted to propellant-free or different propellant aerosol systems (common with later regulatory and supply trends), the practical relevance of claim limitations can be reduced.
What litigation or licensing posture is implied by the claim structure?
Quick answer: The claims are well suited to formulation sampling and lot testing. In disputes, parties can focus on:
- propellant identity and ratio,
- water content (API and formulation),
- particle size distribution by weight,
- vapor pressure measurements.
Typical proof themes:
- laboratory particle sizing,
- chromatographic assay of propellant components,
- moisture analysis,
- vapor pressure testing under defined temperature conditions.
When does exclusivity end: how to time market risk for US 4,405,598?
Quick answer: Patent term and any regulatory exclusivity depend on the filing/priority and maintenance history, plus whether Orange Book listings tie into reference-listed drug exclusivity. The claim text alone does not supply filing dates, priority, or patent term schedule.
Key Takeaways
- Scope is narrow but precise. US 4,405,598 covers an asthma treatment method and corresponding inhalation composition defined by particle size, surfactant, propellant chemistry, propellant ratio, moisture limits, and vapor pressure.
- Propellant system is the main “escape lever.” A product using a different propellant blend or ratio likely falls outside coverage.
- Water and vapor pressure constraints are material. Even with correct propellants, moisture or vapor pressure outside the specified bands can avoid the claims.
- Claim 2 adds another measurement gate. Meeting claim 1 does not guarantee claim 2, because claim 2 requires >=50% (w/w) particles 2–5 microns and a narrower surfactant range.
FAQs
1) What happens if a product’s propellant includes trace trichloromonofluoromethane?
Claim 1 allows “substantially no,” while claim 3 uses “consisting essentially of,” which is stricter against additional components.
2) If MMD is within 0.01–10 microns, can a competitor still avoid claim 2?
Yes. Claim 2 requires >=50% by weight of particles between 2 and 5 microns and a tighter surfactant range.
3) Is the invention limited to metered-dose inhalers?
The claims require a propellant mixture, which is consistent with pressurized aerosols; the claim text provided does not explicitly name an MDI, but propellant-based delivery is strongly implied.
4) Does changing surfactant type avoid infringement?
Yes, if the surfactant is not a sorbitan or sorbitol ester or if it is outside the specified level ranges.
5) Can a moisture-reduction reformulation avoid infringement?
If moisture falls outside either the ingredient-level (API water 0.05–1%) or total formulation water (<0.1%) limits, it can avoid coverage.
References
- U.S. Patent No. 4,405,598 (claims provided in user prompt).
